Molecular regulation of the ?2-adrenergic receptor by long- and short-acting ?-agonists.- Molecular interactions between glucocorticoids and ?2-agonists.- Formoterol, a new long-acting ?2-agonist.- Development of the long-acting ?2-agonist, salmeterol.- Development of bambuterol; a long acting, orally active beta-agonist prodrug.- Development of ?2-receptors in infancy and childhood.- Long-acting beta-agonists in exercise induced asthma.- Salmeterol and oral steroid treatment.- Salmeterol and its relationship to treatment with inhaled corticosteroids.- Long term treatment with formoterol.- Comparison of efficiency of bambuterol and salmeterol.- The future of relievers and controllers in asthma therapy.Springer Book Archives